Annoroad, a Beijing, China-based provider of genomics solutions, raised nearly $105m in Series C funding.
The round was led by Shenzhen GTJA Investment Group and Ping An Ventures with participation from SBCVC, SAIF Partners China, and others.
The company will use the funds for expansion of business scale, constructing talents system, and improving technical research and development, as well as investing in new genomics technology and upstream and downstream enterprises of industrial chain.
Led by Dr. Chongjian Chen, CEO, Annoroad is focusing on the industrialized application of new-generation genomics technology in the field of human medical health and life science research. The company has established a systematic service and product platform in the sectors like R&D and manufacturing of high-throughput gene sequencer and relevant reagents, fertility and reproduction gene testing, genetic disease testing, diagnosis and treatment of tumors, genetic health screening, medical research, scientific research service, gene big data processing, etc.
Annoroad’s NextSeq 550AR sequencer and Non-Invasive Prenatal Testing (NIPT) reagent kit have been approved by CFDA and widely applied in China.
Currently, the company’s sub-brand “AnnoGene” is among the top three within the sequencing service providers in China while SolarGenomics, a cloud-based genomics big data platform, cooperated with Alibaba Cloud. In 2015, it entered into a joint agreement with Illumina, a leader in genomics industry in China, to develop advanced clinical applications for reproductive health using NGS technology.